PeptideLabs Logo
PeptideLabs
Documentación de Calidad
Back to all 64 profiles
Community/research information onlyNo aprobado por FDA/EMAWADA

Community protocol · CJC-1295 no DAC

CJC-1295 no DAC: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: CJC-1295 without DAC · Modified GRF 1-29 · Mod GRF

Sources checked: 27 August 2026

Aviso importante de seguridad y responsabilidad

Esta página documenta y evalúa información de comunidades. No es consejo médico ni terapéutico, asesoramiento individual ni invitación al uso.

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

CJC-1295 no DAC

Se distingue de la versión con DAC y se comenta por la señal de hormona de crecimiento; faltan aprobación y seguridad confirmada.

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amounts, timing and cycles

Community/research information only

No generally accepted approved dose exists. Online amounts vary by material, purity, route and source and prove neither safety nor efficacy.

Amount status

Different amounts circulate online; no regulator-confirmed safe or effective dose exists.

Profile evidence level: preclinical.

Timing

Community claims about time of day, fasting windows or training intervals are not validated clinical standards.

No individual recommendation.

Cycle/duration

Cycles and breaks are community constructs and do not prevent adverse effects or unknown long-term consequences.

No individual recommendation.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Reconstitución y conversión U-100

Calculadora de reconstitución

For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.

Calculadora de reconstitución

Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.

Concentration

3,333.33 µg/ml

Calculated volume

0.06 ml

U-100 units

6 U

Calculated portions per vial

50

Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.

Mechanism and research questions

Shorter-acting GHRH analogue without the drug-affinity complex

CJC-1295 no DAC is classified as “Shorter-acting GHRH analogue without the drug-affinity complex”. Se distingue de la versión con DAC y se comenta por la señal de hormona de crecimiento; faltan aprobación y seguridad confirmada. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Análogo de GHRH

Se examina si un análogo de la hormona liberadora de la hormona del crecimiento estimula a la hipófisis a liberar su propia hormona del crecimiento, como una señal que indica a la glándula que libere. Los investigadores miden los niveles de hormona del crecimiento e IGF-1 en sangre.

02

Mezcla de señalización de hormona del crecimiento

Esto estudia cómo varias sustancias que estimulan cada una la liberación de la hormona del crecimiento son combinadas por los proveedores, de forma similar a pulsar varios botones a la vez para el mismo efecto. Normalmente se estudian los agentes individuales, no el producto combinado.

03

Amplificación del eje de crecimiento

Los investigadores estudian cómo una sustancia amplifica la cadena hormonal natural desde el cerebro hasta la hipófisis y la hormona del crecimiento, en lugar de suministrar la hormona del crecimiento directamente. Se miden los niveles hormonales a lo largo del tiempo y la masa muscular o grasa.

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Foros de culturismo

Aquí se comparan el crecimiento muscular, las ganancias de fuerza y los tiempos de recuperación entre diferentes péptidos de crecimiento y reparación, a menudo basándose en registros de entrenamiento personales. Las afirmaciones de proveedores y usuarios sobre las ganancias musculares son experiencias anecdóticas, no resultados de estudios controlados.

Foros antienvejecimiento

Aquí se comparan combinaciones de péptidos del eje de crecimiento, mitocondriales y de la piel con el objetivo de influir en los signos visibles o percibidos del envejecimiento, a menudo documentados personalmente durante años. Las anécdotas y la publicidad de proveedores sobre el envejecimiento ralentizado no son una prueba científica.

Discusión de origen y pureza

Se discute qué proveedores se consideran más confiables y cómo difieren los resultados de las pruebas de pureza entre lotes. Estas evaluaciones comunitarias se basan en muestras limitadas y no reemplazan las pruebas de laboratorio independientes de cada lote individual.

Adverse effects and risk boundaries

  • Interferir con los ejes de GH, IGF-1 u otras hormonas puede causar edema, molestias articulares o nerviosas, intolerancia a la glucosa y cambios de presión u hormonales; faltan datos humanos fiables para muchas sustancias.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

  • Cáncer activo o previo, diabetes no controlada, enfermedad intracraneal, embarazo/lactancia y trastornos hormonodependientes exigen valoración especializada; los productos aprobados tienen contraindicaciones específicas.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • En un uso médicamente justificado pueden ser relevantes IGF-1, glucosa en ayunas/HbA1c, presión, peso/edema, tiroides y hormonas específicas; no es un esquema de autoanálisis.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Preclínico

La aprobación y la seguridad confirmada faltan por igual en ambas variantes.

Published evidence

Los datos disponibles provienen principalmente de modelos animales o celulares; faltan datos sólidos de eficacia y seguridad en humanos.

Sin la unión al complejo de afinidad por fármacos, esta variante actúa notablemente menos tiempo que el CJC-1295 con DAC.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

No aprobado por FDA/EMA

No existe medicamento aprobado por FDA o EMA; eficacia y seguridad no están establecidas.

WADA 2026

This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile